logo
Plus   Neg
Share
Email

Bayer Says Xarelto Proven Effective In Treating Patients With Pulmonary Embolism

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the oral anticoagulant Xarelto, or rivaroxaban, used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist, in treating patients with acute symptomatic pulmonary embolism and preventing them from developing a secondary venous blood clot.

Rivaroxaban showed similar overall bleeding rates, but was associated with significantly lower rates of major bleeding versus the current standard of care.

The company noted that Rivaroxaban was also proven effective in preventing recurrent venous blood clots in Phase III EINSTEIN-PE Study.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT